Hydra Biosciences, Inc.

Hydra Biosciences, Inc.

Hydra Biosciences, Inc.

Date Founded



405 Concord Avenue,Suite 147,Belmont, MA 02478

Type of Company


Employees (Worldwide)

11 - 50


Medical Support Services
Holding Companies

Company Description

Hydra Biosciences, Inc. develops pharmaceutical products. It is focused in major therapeutic areas, which include pain, inflammation, renal, anxiety, and pulmonary diseases. The company was founded by Laurie Bartlett Keating, Dean Y. Li, David E. Clapham, and Mark T. Keating in 2001 and is headquartered in Belmont, MA.

Contact Data
Trying to get in touch with decision makers at Hydra Biosciences, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Senior Vice President, Chemistry, Pharmacology & Preclinical Development, Consultant

Director of Target Discovery

Director of Clinical Operations

Board of Directors

General Partner, BioPharmaceuticals at LSV Capital Management LLC

Chief Executive Officer & Director at Adenium Biotech ApS

Paths to Hydra Biosciences, Inc.
Potential Connections via
Relationship Science
Hydra Biosciences, Inc.
Recent Transactions
Details Hidden

Hydra Biosciences, Inc. raised money in a private placement transaction

Advisors & Consultants
Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Non-Profit Donations & Grants
Details Hidden

Lilly Ventures invests in companies located in the US. The firm focuses on companies operating in the fields of life sciences, biotechnology, medical technology and healthcare information technology sectors. They provide financing for seed, early and later stage capital requirements.

Details Hidden

Advanced Technology Ventures' (ATV) investment strategy focuses on emerging growth technology businesses in information technology, healthcare and clean technology. The majority of their portfolio companies are based in North America with a few located in Europe and Israel. They target companies with exceptional management teams with solid operational experience and deeply rooted domain expertise. ATV's investment strategy is rooted in portfolio diversification, minimal reliance on stock- market performance, active monitoring of portfolio companies and disciplined management of existing investments. They typically originate and lead initial syndications of their investments. Once an investment has been syndicated, ATV remains actively involved in board membership and helps in a variety of functional, strategic and financial roles. In particular, they assist their portfolio companies in developing their management teams, refining their competitive strategies and strengthening industry alliances.

Details Hidden

MedImmune Ventures invests in both public and private biotechnology companies located across the globe primarily in North America. The firm targets companies operating in the fields of molecules, vaccines, pharmaceutical technologies, medical devices, diagnostics, imaging and healthcare IT. The firm provides financing for seed, early, later and mezzanine stage capital requirements with an investment size ranging from $5 to $10 million per round.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Hydra Biosciences, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Hydra Biosciences, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Hydra Biosciences, Inc..